Azat Tagirdzhanov

Azat Tagirdzhanov

Auto-generated profile, based on publicly available information

Azat Tagirdzhanov

Helmholtz Centre for Infection Research (HZI) Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) Saarbrücken 66123

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
LCLiu Cao
Liu Cao
MGMustafa Guler
Mustafa Guler
ATAzat Tagirdzhanov
Azat Tagirdzhanov
YLYi-Yuan Lee
Yi-Yuan Lee
Alexey GurevichAlexey Gurevich
Alexey Gurevich
Hosein MohimaniHosein Mohimani
Hosein Mohimani
Identification of small molecules is a critical task in various areas of life science. Recent advances in mass spectrometry have enabled the collection of tandem mass spectra of small molecules from hundreds of thousands of environments. To identify which molecules are present in a sample, one can search mass spectra collected from the sample against millions of molecular structures in small molecule databases. The existing approaches are based on chemistry domain knowledge, and they fail to explain many of the peaks in mass spectra of small molecules. Here, we present molDiscovery, a mass spectral database search method that improves both efficiency and accuracy of small molecule identification by learning a probabilistic model to match small molecules with their mass spectra. A search of over 8 million spectra from the Global Natural Product Social molecular networking infrastructure shows that molDiscovery correctly identify six times more unique small molecules than previous methods.

22 November 2023 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
PHPascal Hirsch
Pascal Hirsch
ATAzat Tagirdzhanov
Azat Tagirdzhanov
AKAleksandra Kushnareva
Aleksandra Kushnareva
IOIlia Olkhovskii
Ilia Olkhovskii
SGSimon Graf
Simon Graf
Alexey GurevichAlexey Gurevich
Alexey Gurevich
The human microbiome has emerged as a rich source of diverse and bioactive natural products, harboring immense potential for therapeutic applications. To facilitate systematic exploration and analysis of its biosynthetic landscape, we present ABC-HuMi: the Atlas of Biosynthetic Gene Clusters (BGCs) in the Human Microbiome. ABC-HuMi integrates data from major human microbiome sequence databases and provides an expansive repository of BGCs compared to the limited coverage offered by existing resources. Employing state-of-the-art BGC prediction and analysis tools, our database ensures accurate annotation and enhanced prediction capabilities. ABC-HuMi empowers researchers with advanced browsing, filtering, and search functionality, enabling efficient exploration of the resource. At present, ABC-HuMi boasts a catalog of 19 218 representative BGCs derived from the human gut, oral, skin, respiratory and urogenital systems. By capturing the intricate biosynthetic potential across diverse human body sites, our database fosters profound insights into the molecular repertoire encoded within the human microbiome and offers a comprehensive resource for the discovery and characterization of novel bioactive compounds. The database is freely accessible at https://www.ccb.uni-saarland.de/abc_humi/.

11 October 2021 in Metabolites
Verified
Journal Article
Open access
PDF file
OKOlga Kunyavskaya
Olga Kunyavskaya
ATAzat M. Tagirdzhanov
Azat M. Tagirdzhanov
ARANDRES MAURICIO CARABALLO RODRIGUEZ
ANDRES MAURICIO CARABALLO RODRIGUEZ
LNLouis-Félix Nothias
Louis-Félix Nothias
PDPieter C. Dorrestein
Pieter C. Dorrestein
Alexey GurevichAlexey Gurevich
Alexey Gurevich
Microbial natural products are a major source of bioactive compounds for drug discovery. Among these molecules, nonribosomal peptides (NRPs) represent a diverse class of natural products that include antibiotics, immunosuppressants, and anticancer agents. Recent breakthroughs in natural product discovery have revealed the chemical structure of several thousand NRPs. However, biosynthetic gene clusters (BGCs) encoding them are known only for a few hundred compounds. Here, we developed Nerpa, a computational method for the high-throughput discovery of novel BGCs responsible for producing known NRPs. After searching 13,399 representative bacterial genomes from the RefSeq repository against 8368 known NRPs, Nerpa linked 117 BGCs to their products. We further experimentally validated the predicted BGC of ngercheumicin from Photobacterium galatheae via mass spectrometry. Nerpa supports searching new genomes against thousands of known NRP structures, and novel molecular structures against tens of thousands of bacterial genomes. The availability of these tools can enhance our understanding of NRP synthesis and the function of their biosynthetic enzymes.

26 September 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
GSGeorges P. Schmartz
Georges P. Schmartz
JRJacqueline Rehner
Jacqueline Rehner
MSMiriam J. Schuff
Miriam J. Schuff
LMLeidy Alejandra Gonzalez Molano
Leidy Alejandra Gonzalez Molano
SBSoeren Becker
Soeren Becker
AKAndreas Keller
Andreas Keller
Understanding human, animal, and environmental microbiota is essential for advancing global health and combating antimicrobial resistance (AMR). We investigate the oral and gut microbiota of 48 animal species in captivity, comparing them to those of wildlife animals. Specifically, we characterize the microbiota composition, metabolic pathways, AMR genes, and biosynthetic gene clusters (BGCs) encoding the production of specialized metabolites. Our results reveal a high diversity of microbiota, with 585 novel species-level genome bins (SGBs) and 484 complete BGCs identified. Functional gene analysis of microbiomes shows diet-dependent variations. Furthermore, by comparing our findings to wildlife-derived microbiomes, we observe the impact of captivity on the animal microbiome, including examples of converging microbiome compositions. Importantly, our study identifies AMR genes against commonly used veterinary antibiotics, as well as resistance to vancomycin, a critical antibiotic in human medicine. These findings underscore the importance of the ‘One Health’ approach and the potential for zoonotic transmission of pathogenic bacteria and AMR. Overall, our study contributes to a better understanding of the complexity of the animal microbiome and highlights its BGC diversity relevant to the discovery of novel antimicrobial compounds.

29 May 2023 in ChemRxiv
Verified
Preprint
Open access
PDF file
MBMichael Backenköhler
Michael Backenköhler
PKPaula Linh Kramer
Paula Linh Kramer
JGJoschka Groß
Joschka Groß
GGGerrit Großmann
Gerrit Großmann
RJRoman Joeres
Roman Joeres
AVAndrea Volkamer
Andrea Volkamer
TeachOpenCADD is a free online platform that offers solutions to common computer-aided drug design (CADD) tasks using Python programming and open-source data and packages. The material is presented through interactive Jupyter notebooks, accommodating users from various backgrounds and programming levels. Due to the tremendous impact of deep learning (DL) methods in drug design, the TeachOpenCADD platform has been expanded to include an introduction to molecular DL tasks. This edition provides an overview of DL and its application in drug design, highlighting the usage of diverse molecular representations in this field. The platform introduces various neural network architectures, including graph neural networks (GNNs), equivariant graph neural networks (EGNNs), and recurrent neural networks (RNNs). It demonstrates how to use these architectures for developing predictive models for molecular property and activity prediction, exemplified by the Quantum Machine $9$ (QM$9$), ChEMBL, and Kinase Inhibitor BioActivity (KiBA) data sets. The DL edition covers methods for evaluating the performance of neural networks using uncertainty estimation. Furthermore, it introduces an application of GNNs for protein-ligand interaction predictions, incorporating protein structure and ligand information. The TeachOpenCADD platform is continuously updated with new content and is open to contributions, bug reports, and questions from the community through its GitHub repository (\url{github.com/volkamerlab/teachopencadd}). It can be used for self-study, classroom instruction, and research applications, accommodating users from beginners to advanced levels.

12 February 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
AAAmay Ajaykumar Agrawal
Amay Ajaykumar Agrawal
RGRonald Garcia
Ronald Garcia
GCGuangyi Chen
Guangyi Chen
Chantal Denise BaderChantal Denise Bader
Chantal Denise Bader
PSPeter Sullivan
Peter Sullivan
RMRolf Müller
Rolf Müller
Natural products remain vital sources of therapeutics, particularly anti-infectives, and members of the phylum Myxococcota constitute an especially rich reservoir for their discovery. Based on decades of microbiological efforts, we present 154 new Myxococcota genomes and propose a revised taxonomy expanding the number of described families from 11 to 28 and genera from 32 to 90. Comparison with an equivalent set from the prime source Actinomycetota shows that Myxococcota possess a comparable biosynthetic diversity, underscoring their promise for large-scale isolation and sequencing efforts. The vast untapped potential reflected in 2,387 uncharacterized gene cluster families is highlighted by genome mining efforts, yielding four validated compounds exhibiting novel chemistry, including myxolutamids and myxopentacins. We show that many Myxococcota-derived natural products, such as myxolutamid A and two new sorangicin derivatives, are conserved within taxonomic lineages. New described families thus bear high biosynthetic potential underpinning the importance of precise taxonomic classification guiding targeted drug discovery.